Mark T. Fleming, MD, discusses the potential impact of positive data from the phase 3 SPOTLIGHT study, which assessed the how 18F-rhPSMA-7.3 PET scan use in male patients with biochemical recurrence of prostate cancer affects upstaging in comparison with conventional imaging.
Mark T. Fleming, MD, a medical oncologist at Virginia Oncology Associates, discusses the potential impact of positive data from the phase 3 SPOTLIGHT study, which assessed how 18F-rhPSMA-7.3 PET scan use in male patients with biochemical recurrence of prostate cancer affects upstaging in comparison with conventional imaging.
Results from 366 patients in the study showed that the frequency of post-scan upstaging was higher with 18F-rhPSMA-7.3 vs conventional imaging, particularly in patients with intact prostate. Based on the study findings, investigators predict that 18F-rhPSMA-7.3 PET scan may help with the definition of sites of disease recurrence and provide better information for salvage therapy decisions.
According to Fleming, the success of the SPOTLIGHT study could lead to an FDA approval and offer another option for patients with prostate cancer.
0:07 | Hopefully, you know, it will meet FDA approval to add a yet another option for patients. And that's what it's all about is providing as many options for patients as can be. There were some differences with regard to whether someone had a prostatectomy. There was whether someone had radiation therapy and the site of disease recurrence, whether it was in the prostate bed, pelvic lymph nodes or outside so it's always nice to see the field advancing.
0:36 | I think it further goes to show that that standard conventional imaging is inadequate and we're having yet hopefully have another agent to further clarify and provide information for patients and their families.